Tazocilin (2 gm+0.25 gm)/vial (IV Infusion)
2.25 gm vial: ৳ 550.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Piperacillin tazobactam |
| Company | Square pharmaceuticals plc |
| Also available as |
Title
- Piperacillin and Tazobactam Injection
Categories
- Antibiotic
- Intravenous Solution
- Pharmacological Drug
- Therapeutic Medication
Indications
- Treatment of moderate to severe intra-abdominal infections
- Treatment of skin and skin structure infections
- Treatment of female pelvic infections
- Treatment of community-acquired pneumonia
- Treatment of nosocomial pneumonia
- Effective against susceptible isolates of designated bacteria
Pharmacology
- Broad spectrum penicillin
- Bactericidal activity against gram-positive and gram-negative bacteria
- Inhibition of septum and cell wall synthesis
- Potent inhibitor of beta-lactamases
Dosage & Administration
- To be administered by intravenous infusion over 30 minutes
- Adult dose: 3.375g every six hours
- Pediatric dosage based on age and body weight
- Duration of treatment: 7 to 14 days depending on the condition
Interactions
- Potential interactions with aminoglycosides, probenecid, anticoagulants, vecuronium, and methotrexate
Contraindications
- Allergic reactions to penicillins, cephalosporins, or beta-lactamase inhibitors
Side Effects
- Adverse events involving the skin, gastrointestinal system, immune system, infections, metabolism, musculoskeletal system, psychiatric disorders, vascular system, and respiratory system
- Range of reported side effects including rash, pruritus, diarrhea, constipation, nausea, vomiting, hypersensitivity reactions, hypoglycemia, myalgia, and epistaxis
Pregnancy & Lactation
- Crosses the placenta in humans
- Insufficient data for safety in pregnant women
- Excreted in human milk
Precautions & Warnings
- Reported instances of serious hypersensitivity reactions, severe cutaneous adverse reactions, and hematological effects
- Nephrotoxicity observed in critically ill patients
- Clostridium difficile associated diarrhea to be evaluated if it occurs
Use in Special Populations
- Supported use in pediatric patients 2 months of age and older
- Dosage adjustment for patients with renal impairment
- No dosage adjustment warranted in patients with hepatic cirrhosis
- Increased incidence of fever and rash in cystic fibrosis patients
Overdose Effects
- Reported overdose effects including nausea, vomiting, diarrhea, neuromuscular excitability, and convulsions
- Supportive and symptomatic treatment recommended
Therapeutic Class
- Broad spectrum penicillins
- Other beta-lactam antibiotics
Reconstitution
- Preparation of solution for intravenous infusion using 0.9% Sodium Chloride solution
- Detailed instructions for reconstitution and administration
- Storage guidelines for reconstituted solution
Storage Conditions
- Storage temperature below 30°C
- Protection from light and moisture
- Keep out of reach of children